Head-to-Head Study Reports Patient Comfort With Visipaque (iodixanol) And Isovue (iopamidol) During Peripheral Arteriography

GE Healthcare today announced results from a new study, which showed that patients receiving Visipaque tm (iodixanol) 320mg I/ml reported less discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving Isovue ® (iopamidol) 370 mg I/ml during peripheral arteriography. As with other iodinated contrast agents, Visipaque is often associated with sensations of discomfort, warmth or pain. The data were presented at the American College of Cardiology’s 63 rd Annual Scientific Session and Expo. 1

“Contrast-induced discomfort is commonly seen in patients undergoing peripheral arteriography,” said Thomas Todoran, M.D., lead author of the study and Assistant Professor of Medicine, Director of Vascular Medicine at Medical University of South Carolina. “Patient discomfort continues to be a challenge, primarily because of potential for body movement that may lead to image degradation. Results from this study showed that Visipaque use led to significantly less patient discomfort, heat or pain when compared to Isovue. The results of this comparative study suggest that Visipaque may be a preferable contrast agent for use in peripheral arteriography.”

While this study was not powered to detect a difference in image quality, the number of subjects with image quality rated as excellent was numerically greater in the Visipaque group (86.5%) versus the Isovue group (82.4%), but the difference was not statistically significant. Discomfort impacted image quality in 6.5% of Isovue subject images and in 3.2% of Visipaque subject images.

About the Study

This prospective, multicenter, randomized, double-blind, parallel group, comparative study evaluated and compared contrast-induced patient discomfort, overall safety and image quality following contrast administration in 253 patients receiving either Visipaque 320mg I/mL or Isovue 370mg I/mL, The study conducted at 13 sites throughout Europe and the United States. Of these, 249 patients (125 Visipaque, 124 Isovue) completed discomfort assessments. Contrast-induced discomfort, specifically coldness, heat or pain, was assessed within 10 minutes following each contrast injection and rated verbally by the patient on a 0-to-10 scale.

If you liked this article you might like

CEOs Are Dropping Like Flies

How To Get a Promotion Using Legendary Former GE Head Jack Welch's Strategies

GE Nearing Deal to Sell Industrial Solutions Unit to Swiss-Based ABB

How to Fire People Like Former General Electric CEO Jack Welch

Tax Reform Is Coming and That Means Trump Stock Rally Is Ready to Kill It Again